Goedkoop worked in start-up and large biopharmaceutical companies such as EryDel, Centocor, Eli Lilly, Serono, Modex or Apoxis, and directly interacted with key regulatory agencies (FDA, EMA, Korea, Japan and China). As an independent consultant, he conducted due diligences and helped develop business plans for de novo biotech companies for venture capital investors. He holds an M.D. from the University of Amsterdam.